Fengcai Zhu to Vaccines, Synthetic
This is a "connection" page, showing publications Fengcai Zhu has written about Vaccines, Synthetic.
Connection Strength
0.709
-
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med. 2021 06; 27(6):1062-1070.
Score: 0.356
-
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 06 13; 395(10240):1845-1854.
Score: 0.083
-
Dynamics of 8G12 competitive antibody in "prime-boost" vaccination of Hepatitis E vaccine. Hum Vaccin Immunother. 2017 06 03; 13(6):1-6.
Score: 0.067
-
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017 02 11; 389(10069):621-628.
Score: 0.066
-
Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2017 03; 5(3):e324-e334.
Score: 0.066
-
Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults. Vaccine. 2014 Jun 17; 32(29):3706-12.
Score: 0.054
-
A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine. Vaccine. 2017 09 05; 35(37):5073-5080.
Score: 0.017